Ofri Mosenzon MD, MScHead of Diabetes Clinical Research Center, Diabetes Unit; Faculty of Medicine, Hebrew University of Jerusalem; Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.
Ofri Mosenzon is Manager of the Diabetes Clinical Research Center at the Hadassah Hebrew University Hospital, Jerusalem, Israel, where she also teaches Endocrinology, Internal Medicine and Epidemiology. Dr Mosenzon received her medical degree from the Faculty of Medicine, Technion, Haifa, Israel. She is board-certified in Internal Medicine and Endocrinology, and has an MSc in Clinical Epidemiology from the Hebrew University, Jerusalem.
Since 2010, Dr Mosenzon has been the Principal Investigator of more than 30 phase 2, 3 and 4 clinical trials in the fields of diabetes, diabetic treatments, diabetic complications (nephropathy, retinopathy and neuropathy), cardiovascular endpoints, obesity and hyperlipidaemia. She has initiated, planned and executed clinical research projects that were funded independently from industry. Dr Mosenzon has been involved in the planning, execution and summarising of several large-scale international trials, including Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58.
Dr Mosenzon’s self-initiated research interests include, but are not limited to, glucagon-like peptide-1 receptor analogues, training family physicians as diabetologists, fear of hypoglycaemia, predictive value of normal fasting glucose levels, and diabetes among different ethnic groups and minorities in Israel. She has led many peer-reviewed publications, books, chapters and poster presentations. She is a member of the European Association for the Study of Diabetes, the American Diabetes Association, the Israeli Diabetes National Council, the Israel Association for Endocrinology, and the Israel Diabetes Association.
DisclosuresDr. Mosenzon reports the following:
- Advisory Board: Novo Nordisk, Eli Lilly, sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, BOL Pharma;
- Research grant support through Hadassah Hebrew University Hospital: Novo Nordisk, AstraZeneca;
- Speaker's Bureau: AstraZeneca,
Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme,
Boehringer Ingelheim, Jansen
Recent Contributions to PracticeUpdate:
- Effect of Dapagliflozin on the Rate of Decline in Kidney Function in Patients With CKD With and Without T2D
- Effect of Dapagliflozin on Urinary Albumin Excretion in Patients With CKD With and Without T2D
- Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Reduces the Risk of Major Adverse Kidney Events Compared With Other Antihyperglycemics